Benjamin L. Oakes
@BenjaminLOakes
Followers
967
Following
919
Media
12
Statuses
245
CEO @scribetx | at the interface of molecular and genetic engineering | designing CRISPR to be safe enough for all
Joined April 2011
RT @scribetx: What if your DNA didn’t define your health destiny?. In his @TEDx Talk, our CEO @BenjaminLOakes reimagines a future where any….
0
4
0
RT @mcuban: Disintermediating PBM middlemen would save Americans $100b a year says USC research. They nailed it .
academic.oup.com
Abstract. Recent concerns over rising drug prices have focused on the role of pharmacy benefit managers or PBMs. While multiple players make up the pharmac
0
454
0
RT @scribetx: 💡 Read @TheScientistLLC's latest Innovation Spotlight interviewing our CEO @BenjaminLOakes about how next-generation #CRISPR….
the-scientist.com
Benjamin Oakes from Scribe Therapeutics shares how exciting advancements in CRISPR-based gene and epigenetic editing therapies impact the future of cardiovascular and cardiometabolic disease manage...
0
4
0
RT @scribetx: No patient should be left behind. Millions in the U.S. can't wait. Our CEO @BenjaminLOakes joined the @NPLB_org campaign to….
0
3
0
RT @scribetx: “In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients i….
genengnews.com
Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for pushing CRISPR cures to the clinic.
0
8
0
Big thanks to @blalpert & @mackenziettnni for sitting down with us to hear more about why the future of cardiometabolic disease 🫀 is looking bright💡. At Scribe, our aim is to build medicines that are safe, effective, and durable enough to be both highly preventative and broadly.
In this feature, @barronsonline highlights that “genetic-medicine approaches to PCSK9 are exploring nonpermanent, but long-lasting fixes . Scribe Therapeutics has reported intriguing results in monkeys from ‘epigenetic’ edits of the molecules that turn genes on and off.”.
0
1
3
RT @SebastianCaliri: Many people have no sense of how quickly Chinese biotech is catching up to the US. If we do not reduce clinical devel….
0
27
0
Over the past few weeks, we've had the privilege of sharing our groundbreaking results, highlighting the cutting-edge advancements of our engineered CRISPR technologies across multiple areas. Most notably, we've demonstrated that the durability of our epigenetic approach to.
This month, we presented positive data on our #CRISPR technologies at the 2025 @EASCongress and @ASGCTherapy Annual Meeting. For more details, read our thread and press release below 👇
2
3
21
RT @scribetx: This month, we presented positive data on our #CRISPR technologies at the 2025 @EASCongress and @ASGCTherapy Annual Meeting.….
0
2
0
RT @scribetx: @EliLillyandCo @ASGCTherapy Our second #ASGCT2025 presentation takes place this afternoon. This joint session with @EliLillya….
0
1
0
RT @scribetx: Attending #ASGCT2025 🧬 in New Orleans?. Be sure to check out our first presentation today on novel #CRISPR genome editing str….
0
4
0
At Scribe, the hits just keep on coming. 🔬🚀🫀. Check it out: Tomorrow at the 93rd European Atherosclerosis Society (EAS) Congress, our CSO Dr. Aarif Khakoo will present Scribe's breakthrough preclinical data from our lead epigenetic silencing program, STX-1150. 📢. Built on our.
Join us at #EASCongress2025 where our CSO Aarif Khakoo will deliver a late-breaking presentation with data on our #CRISPR epigenetic silencing technology ELXR for LDL-C lowering. To learn about our advances developing ELXR for cardiometabolic disease at @EASCongress, read on 👇
0
1
6
Today I am proud to share important progress from @scribetx in collaboration with @EliLillyandCo in advancing CRISPR-based therapies and delivery systems for neurological diseases. 🛠️ Reaching this milestone, and our upcoming presentation at #ASGCT2025, underscores the strength.
We’re pleased to announce the achievement of a success milestone in our collaboration with Prevail Therapeutics, a part of @EliLillyandCo’s Gene Therapy Division, to develop in vivo #CRISPR-based therapeutics for neurological and neuromuscular disorders. Highlights below 🧵
0
2
4
🔥 Fund, Baby, Fund!.A recent report shows NIH delivers an approximate 250% ROI per dollar. Yet in real, inflation-adjusted terms, NIH funding has been flat or declining for 25 years. That doesn’t preserve our lead — it erodes it, bad. The first solution must be: Fund, Baby,.
0
2
3
As I mentioned a few days ago, the Senate just released a report on U.S. biotech competitiveness. It makes one thing very clear:. 🧬 Biotech is strategic infrastructure. The global healthcare market is estimated at $21T—three times the size of the global energy market. Let that.
🚨 Can we stop the offshoring of U.S. biotech?. A Senate report dropped today with a clear warning: U.S. biotech is at risk of falling behind as China’s state-backed sector rapidly accelerates. While there’s a lot of analysis in the report I see one major trend it misses:. 👉.
2
8
48
🚨 Can we stop the offshoring of U.S. biotech?. A Senate report dropped today with a clear warning: U.S. biotech is at risk of falling behind as China’s state-backed sector rapidly accelerates. While there’s a lot of analysis in the report I see one major trend it misses:. 👉.
10
14
82